Manufacturing and testing of an allogeneic gamma delta T cell therapy for the treatment of cancer

Project Information

OmnImmune

Grant agreement ID: 783506

DOI 10.3030/783506

Closed project

EC signature date 29 November 2017

Start date 1 October 2017

End date 30 September 2019

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 3 957 000,00

EU contribution € 3 957 000,00

Coordinated by

TC BIOPHARM LIMITED
United Kingdom